In an adult with recurrent Clostridioides difficile infection (CDI), what are the indications for fecal microbiota transplant (FMT) and the recommended procedure for its administration?

Fecal Microbiota Transplant for Recurrent Clostridioides difficile Infection

Offer FMT to all adults with two or more recurrences of CDI after completing at least 10 days of appropriate antibiotic therapy. 1 This represents the clearest indication where FMT should be standard of care, with cure rates approaching 90%.

Primary Indications for FMT

Recurrent CDI (Outpatient Setting)

• First recurrence: Consider FMT as an option, though antibiotics remain acceptable 1
• Two or more recurrences: FMT should be offered to all patients 1
• Refractory CDI: Consider FMT as adjunct to antibiotics 1

Severe/Fulminant CDI (Hospitalized Patients)

Consider FMT within 2-5 days for hospitalized patients with severe or fulminant CDI not responding to standard antibiotics. 2 This represents an earlier intervention point when patients are deteriorating despite appropriate antimicrobial therapy.

• Severe CDI defined as: WBC ≥15 × 10⁹/L and/or creatinine ≥1.5 mg/dL
• Fulminant CDI: severe disease with shock, ileus, or megacolon
• Contraindications: bowel perforation, obstruction, or severe immunocompromise 2

Pre-FMT Requirements

All patients must complete at least 10 days of appropriate CDI antibiotics before FMT. 1 This is non-negotiable and ensures active infection is adequately treated before microbiome restoration.

Administration Routes and Recommendations

Route Selection by Clinical Scenario

For severe/fulminant hospitalized CDI:

• First-line route: Colonoscopy or flexible sigmoidoscopy 2
• Colonoscopy allows confirmation of diagnosis and assessment of severity
• Avoid: Nasoenteric tube (increased aspiration risk) 2
• Avoid: Capsules or enemas (insufficient evidence in severe disease) 2
• Bowel preparation may not be feasible or safe—proceed without if necessary 2

For recurrent CDI (outpatient/stable patients):

• Multiple routes are acceptable with insufficient evidence to recommend one over another 2
• Colonoscopy may be superior to capsules, particularly in patients ≥65 years old 3
  • Recent 2026 prospective cohort (n=652) showed capsule FMT had higher 1-month recurrence (18% vs 7.4%, P=0.001) 3
  • Effect most pronounced in elderly (≥65 years): adjusted OR 2.7 for recurrence with capsules 3
  • In patients <65 years, routes appear equivalent 3

Practical Algorithm for Route Selection:

1. Age ≥65 years with recurrent CDI: Prefer colonoscopy over capsules 3
2. Age <65 years with recurrent CDI: Either colonoscopy or capsules acceptable
3. Severe/fulminant CDI: Colonoscopy or flexible sigmoidoscopy only 2
4. Patient preference/procedural risk: Balance efficacy against colonoscopy risks

Donor Selection and Preparation

Use universal (unrelated) donors over related donors. 1 Universal donors undergo more rigorous screening protocols.

Donor Screening Requirements:

• Questionnaire/interview for transmissible disease risk factors 1
• Blood and stool testing for infectious diseases 1
• Periodic rescreening (no longer than 4-month intervals) 1
• Health assessment at each donation 1

FMT Preparation:

• Use frozen FMT over fresh preparations 1
• Aerobic or anaerobic processing both acceptable 1
• Store at -70°C for up to 12 months 1
• Add cryoprotectant (e.g., glycerol) 1
• Quarantine until post-baseline screening complete 1

Special Populations

Immunocompromised Patients

Mildly/moderately immunocompromised: Offer conventional FMT 2

Severely immunocompromised: Avoid FMT 2

• Active cytotoxic chemotherapy
• CAR-T or hematopoietic cell transplant (when neutropenic)
• Any neutropenia
• Severe primary immunodeficiency
• Advanced/untreated HIV (CD4 <200/mm³)

Critical caveat: FDA-approved microbiome products (fecal microbiota spores live-brpk, fecal microbiota live-jslm) have insufficient evidence in immunocompromised patients 2

Other Considerations:

• Do not refuse FMT based on age >75 years 1
• Contraindication: Known anaphylactic food allergy 1
• IBD patients: Warn about small risk of disease exacerbation 1

Post-FMT Management

• Follow-up for at least 8 weeks to assess efficacy and adverse events 1
• Do not test for C. difficile cure unless persistent symptoms or suspected relapse 1
• If initial FMT fails: Offer one or more additional FMTs 1
• Consider alternative diagnoses if no response to FMT 1

Common Pitfalls

1. Using capsules in elderly patients: Recent evidence suggests colonoscopy is superior in those ≥65 years 3
2. Attempting FMT in severely immunocompromised patients: High risk, avoid 2
3. Using nasoenteric tubes in severe CDI: Aspiration risk too high 2
4. Inadequate antibiotic course pre-FMT: Must complete ≥10 days 1
5. Testing for cure post-FMT: Only test if symptomatic 1

Alternative Therapies

When FMT is not desired or available: vancomycin taper, tapered-pulsed fidaxomicin, or bezlotoxumab are reasonable alternatives 2. However, access barriers (insurance coverage, cost, availability) significantly limit these options in practice 4.